

IN THE CLAIMS:


The following listing of claims replaces all prior versions:

1. (Canceled)

2. (Currently amended) The method of claim [[1]] 40, wherein the water-soluble substituent is  ~~$-\text{O}-(\text{C}=\text{O})-\text{CH}_2-\text{N}(\text{CH}_3)_2\cdot\text{Cl}$~~   $-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}(\text{CH}_3)_2\cdot\text{Cl}$ .
3. (Currently amended) The method of claim [[1]] 40, wherein the host is infected with Herpes simplex virus.
4. (Currently amended) The method of claim [[1]] 40, wherein the water-soluble substituent is  ~~$-\text{O}-(\text{C}=\text{O})-\text{CH}_2-\text{NH}_2$~~   $-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}_2$ .
5. (Currently amended) The method of claim [[1]] 40, wherein the ~~substantially purified compound inhibited~~ inhibits viral transcription.
6. (Currently amended) The method of claim [[1]] 40, wherein the ~~substantially purified compound inhibited~~ inhibits transactivation of viral gene.
7. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutane (4-O-methyl-NDGA).
8. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3-O-methyl-4-O-acetyl-NDGA).
9. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,3',4-tri-O-methyl-NDGA).


10. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,4,4'-tri-O-methyl-NDGA).
11. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (3',4-di-O-methyl-3-O-acetyl-NDGA).
12. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,3'-di-O-methyl-4-O-acetyl-NDGA).
13. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (4,4'-di-O-methyl-3-O-acetyl-NDGA).
14. (Currently amended) The method of claim [[1]] 40, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,4'-di-O-methyl-4-O-acetyl-NDGA).
15. (Currently amended) A method of inhibiting replication of an acyclovir-resistant virus in a cell comprising the steps of:

(a) providing a substantially purified compound having a formula:



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are each selected from the group consisting of HO-,  $\text{CH}_3\text{O}$ - and  $\text{CH}_3(\text{C}=\text{O})\text{O}$ -, or and a water soluble substituent, wherein the water soluble


substituent is selected from the group consisting of:  $-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}(\text{CH}_3)_2.\text{Cl}.$  -  
 $\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}_3,$




(b) contacting the cell with the substantially purified compound.

16. (Currently amended) A method of treatment of acyclovir-resistant viral infection in a subject comprising the steps of:


(a) providing a substantially purified compound having [[a]] the formula:



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are each selected from the group consisting of  $\text{HO}-$ ,  $\text{CH}_3\text{O}-$  and  $\text{CH}_3(\text{C}=\text{O})\text{O}-$ , or and a water soluble substituent, wherein the water soluble substituent is selected from the group consisting of:  $-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}(\text{CH}_3)_2.\text{Cl}.$  -  
 $\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}_3,$



and



;


and

(b) administering the substantially purified compound to the subject.


17. (Currently amended) A method of treatment of a subject infected with a virus, wherein the virus is ~~susceptible to development of resistance~~ resistant to acyclovir comprising the steps of:

(a) providing a composition comprising a substantially purified compound; and


(b) administering a therapeutically effective amount of the compound to the subject, wherein the compound ~~is a derivative of NDGA~~ has the formula:



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are each selected from the group consisting of HO-, CH<sub>3</sub>O- and CH<sub>3</sub>(C=O)O-, and a water soluble substituent, wherein the water soluble substituent is selected from the group consisting of: -O(C=O)CH<sub>2</sub>NH(CH<sub>3</sub>)<sub>2</sub>.Cl, -O(C=O)CH<sub>2</sub>NH<sub>3</sub>,



and



18. (Canceled)

19. (Currently amended) The method of claim ~~18~~ 17, wherein the water-soluble substituent is  $-\text{O}-(\text{C}=\text{O})-\text{CH}_2-\text{NH}_2$   $-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}_2$ .

20. (Currently amended) The method of claim ~~18~~ 17, wherein the water-soluble substituent is  $-\text{O}-(\text{C}=\text{O})-\text{CH}_2-\text{N}(\text{CH}_3)_2 \cdot \text{Cl}$   $-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}(\text{CH}_3)_2 \cdot \text{Cl}$ .


21 (Currently amended) The method of claim 17, wherein the ~~substantially purified~~ compound ~~inhibited~~ inhibits viral transcription.

22. (Currently amended) The method of claim 17, wherein the ~~substantially purified~~ compound ~~inhibited~~ inhibits transactivation of the viral gene.


23. (Previously presented) The method of claim 18, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutane (4-O-methyl-NDGA).

24. (Previously presented) The method of claim 18, wherein the compound is 1-(3,4-dihydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3-O-methyl-4-O-acetyl-NDGA).
25. (Previously presented) The method of claim 18, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,3',4-tri-O-methyl-NDGA).
26. (Previously presented) The method of claim 18, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutane (3,4,4'-tri-O-methyl-NDGA).
27. (Previously presented) The method of claim 18, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (3',4-di-O-methyl-3-O-acetyl-NDGA).
28. (Previously presented) The method of claim 18, wherein the compound is 1-(3-methoxy-4-hydroxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,3'-di-O-methyl-4-O-acetyl-NDGA).
29. (Previously presented) The method of claim 18, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-acetoxy-4-methoxyphenyl)-2,3-dimethylbutane (4,4'-di-O-methyl-3-O-acetyl-NDGA).
30. (Previously presented) The method of claim 18, wherein the compound is 1-(3-hydroxy-4-methoxyphenyl)-4-(3-methoxy-4-acetoxyphenyl)-2,3-dimethylbutane (3,4'-di-O-methyl-4-O-acetyl-NDGA).
- 31-38. (Canceled)


39. (Previously presented) A method of treatment of viral infection in a host comprising the steps of: (a) providing a composition comprising a compound; and (b) administering a viral inhibitory amount of the compound to the host, wherein the compound has the formula selected from the group consisting of:



and



40. (New) A method for suppressing viral growth in a host infected with a virus comprising (a) providing a composition comprising a substantially purified compound; and (b) administering to the host an effective amount of the compound to suppress viral growth, wherein the compound is a derivative of nordihydroguaiaretic acid (NDGA) having the formula:




wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are each selected from the group consisting of  $\text{HO-}$ ,  $\text{CH}_3\text{O-}$  and  $\text{CH}_3(\text{C=O})\text{O-}$ , or a water soluble substituent, provided that  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are not




each HO-, wherein the water soluble substituent is selected from the group consisting of:

$-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}(\text{CH}_3)_2\cdot\text{Cl}$ ,  $-\text{O}(\text{C}=\text{O})\text{CH}_2\text{NH}_3$ ,



and



41. (New) The method of claim 40, wherein  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$  and  $\text{R}_4$  are not each  $\text{CH}_3\text{O}-$  or  $\text{CH}_3(\text{C}=\text{O})\text{O}-$  simultaneously.

42. (New) The method of claim 40, wherein the effective viral growth suppressing amount of the compound is less than  $95\ \mu\text{M}$ .

43. (New) The method of claim 40, wherein the effective viral growth suppressing amount of the compound is less than  $62.7\ \mu\text{M}$ .

44. (New) The method of claim 40, wherein the effective viral growth suppressing amount of the compound is less than  $31.3\ \mu\text{M}$ .

45. (New) The method of claim 40, wherein the effective viral growth suppressing amount of the compound is less than  $25\ \mu\text{M}$ .

46. (New) The method of claim 40, wherein the effective viral growth suppressing amount of the compound is less than  $9.5\ \mu\text{M}$ .